Schlechte J A, Ginsberg B H, Sherman B M
J Steroid Biochem. 1982 Jan;16(1):69-74. doi: 10.1016/0022-4731(82)90145-5.
The presence of a glucocorticoid receptor in human lymphocytes is well established, but factors affecting its regulation have not been described. Using a competitive binding whole cell assay, we have examined the binding of [3H]-dexamethasone at 24 and 37 degrees C in untreated normal subjects and in healthy subjects taking various glucocorticoid preparations. At 24 degrees C normal human lymphocytes had 6000 binding sites/cell and a dissociation constant of 4 x 10(-9) M. The administration of 1 mg of dexamethasone, 5 mg of prednisone, and 37.5 mg of cortisone acetate resulted in a 30% decrease in binding sites after 1 week with no change in binding affinity. No changes in the number of binding sites was noted before 1 week and the diminished number persisted for 1 week after discontinuation of glucocorticoid treatment. Lymphocytes from hospitalized patients taking 40-60 mg of dexamethasone daily demonstrated the same change in number of binding sites that was seen in normal subjects taking 1 mg of dexamethasone. When binding assays were carried out at physiologic temperature there was the same decrease in number of binding sites after dexamethasone administration, and in addition, there was a two-fold increase in binding affinity. Glucocorticoid administration results in a time-dependent decrease in the number of lymphocyte glucocorticoid binding sites that is independent of the type of glucocorticoid administered. This is the first in vivo demonstration that glucocorticoids modulate their own receptors in man.
人类淋巴细胞中糖皮质激素受体的存在已得到充分证实,但影响其调节的因素尚未有描述。我们使用竞争性结合全细胞测定法,在24℃和37℃下检测了[3H] - 地塞米松在未治疗的正常受试者以及服用各种糖皮质激素制剂的健康受试者中的结合情况。在24℃时,正常人淋巴细胞有6000个结合位点/细胞,解离常数为4×10^(-9)M。给予1mg地塞米松、5mg泼尼松和37.5mg醋酸可的松1周后,结合位点减少30%,结合亲和力无变化。在1周前未观察到结合位点数量的变化,糖皮质激素治疗停止后,减少的数量持续1周。每天服用40 - 60mg地塞米松的住院患者的淋巴细胞显示出与服用1mg地塞米松的正常受试者相同的结合位点数量变化。当在生理温度下进行结合测定时,地塞米松给药后结合位点数量同样减少,此外,结合亲和力增加了两倍。糖皮质激素给药导致淋巴细胞糖皮质激素结合位点数量随时间减少,这与所给予的糖皮质激素类型无关。这是首次在体内证明糖皮质激素在人体中调节其自身受体。